GENPHARMA
GENPHARMASEC financials
- Market cap
- ₹64 Cr
Quarterly results
Q1 FY27: revenue up 312.9%, net profit down 113.9% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6 | 8 | 14 | 12 | 33 +441% | 40 +370% | 55 +296% | 50 +313% |
| EBITDA | 0 | 1 | -1 | 1 | -0 −454% | -1 −272% | 2 +299% | 1 +2% |
| Net profit | 1 | 1 | -0 | 1 | -1 −269% | -1 −209% | 1 +604% | -0 −114% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −38.2% 1Y
1Y: ₹1.91 on 9 Sept 2025 → ₹1.18. High ₹2.06 (19 Sept 2025), low ₹0.78 (30 Mar 2026).
Financials, as filed
Revenue grew 315.0% a year over 1 year, FY25 to FY26. Operating margin widened to 0.9%.
| Year ending | FY25 | FY26 |
|---|---|---|
| Revenue | ₹34 Cr | ₹140 Cr |
| Operating profit | ₹0 Cr | ₹1 Cr |
| Operating margin | 0.1% | 0.9% |
| Interest | ₹0 Cr | ₹1 Cr |
| Depreciation | ₹1 Cr | ₹2 Cr |
| Net profit | ₹2 Cr | ₹1 Cr |
| Net margin | 4.5% | 0.4% |
| Cash from operations | ₹3 Cr | ₹-18 Cr |
| Free cash flow | ₹-3 Cr | ₹-21 Cr |
| ROCE | 3.0% | 3.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Equity capital | ₹28 Cr | ₹55 Cr | ₹55 Cr | ₹55 Cr |
| Reserves | ₹-12 Cr | ₹9 Cr | ₹10 Cr | ₹11 Cr |
| Borrowings | ₹3 Cr | ₹4 Cr | ₹11 Cr | ₹35 Cr |
| Other liabilities | ₹1 Cr | ₹3 Cr | ₹47 Cr | ₹37 Cr |
| Total liabilities | ₹20 Cr | ₹71 Cr | ₹124 Cr | ₹138 Cr |
| Fixed assets | ₹0 Cr | ₹1 Cr | ₹42 Cr | ₹41 Cr |
| Capital work in progress | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Investments | ₹1 Cr | ₹19 Cr | ₹2 Cr | ₹2 Cr |
| Other assets | ₹19 Cr | ₹51 Cr | ₹80 Cr | ₹95 Cr |
| Total assets | ₹20 Cr | ₹71 Cr | ₹124 Cr | ₹138 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
The ownership split has held steady since Jun 2025. The shareholder count shrank 6% to 1,01,134.
- Promoters
- 30.0%
- Public
- 70.0%
Since Jun 2025
- Promoters 0.00 pp
- Public 0.00 pp
How it drifted, 12 quarters
Over this window promoters fell from 60.0% to 30.0% — −30.0 pp.
Ownership split by quarter, oldest first. Sep '23: Promoters 60.0%, Public 40.0%.Dec '23: Promoters 60.0%, Public 40.0%.Mar '24: Promoters 30.0%, Public 70.0%.Jun '24: Promoters 30.0%, Public 70.0%.Sep '24: Promoters 30.0%, Public 70.0%.Dec '24: Promoters 30.0%, Public 70.0%.Mar '25: Promoters 30.0%, Public 70.0%.Jun '25: Promoters 30.0%, Public 70.0%.Sep '25: Promoters 30.0%, Public 70.0%.Dec '25: Promoters 30.0%, Public 70.0%.Mar '26: Promoters 30.0%, Public 70.0%.Jun '26: Promoters 30.0%, Public 70.0%.
Who is on the register
Named in the Jun 2026 filing
Every holder of GENPHARMASEC LIMITED above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Sneha Sadhwani | 16.80% | unchanged |
| Rajesh Sadhwani | 13.18% | unchanged |
| Rushabh Sevantilal Sanghavi | 4.42% | −0.28 pp |
| Sadashiv Kanyana Shetty | 2.06% | unchanged |
| Yogeshkumar Rasiklal Sanghavi | 1.77% | unchanged |
| Vishesh Mahesh Nihalani | 1.52% | unchanged |
| L7 Hitech Private Limited | 1.17% | −0.09 pp |
| Narendra Chhaganlal Solanki . | 1.09% | unchanged |
| Nimesh Shambhulal Joshi | 1.01% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Learn to analyse GENPHARMASEC LIMITED
Guides on how to read this kind of business and the numbers that matter.